| Drug General Information |
| Drug ID |
D09OKK
|
| Former ID |
DNC004217
|
| Drug Name |
LG-120838
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C27H25NO
|
| Canonical SMILES |
CC1=CC=CC=C1C=C2C3=C(C=CC4=C3C(=CC(N4)(C)C)C)C5=CC=CC=C<br />5O2
|
| InChI |
1S/C27H25NO/c1-17-9-5-6-10-19(17)15-24-26-21(20-11-7-8-12-23(20)29-24)13-14-22-25(26)18(2)16-27(3,4)28-22/h5-16,28H,1-4H3/b24-15-
|
| InChIKey |
YXKBVHXOKVRRKO-IWIPYMOSSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Mineralocorticoid receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| mRNA of androgen receptor |
Target Info |
Inhibitor |
[1]
|
| mRNA of glucocorticoid receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Aldosterone-regulated sodium reabsorptionhsa04114:Oocyte meiosis
|
|
Pathways in cancer
|
|
Prostate cancerhsa04080:Neuroactive ligand-receptor interaction
|
|
NetPath Pathway
|
EGFR1 Signaling Pathway
|
|
AndrogenReceptor Signaling Pathway
|
|
FSH Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Coregulation of Androgen receptor activity
|
|
Regulation of Androgen receptor activity
|
|
Nongenotropic Androgen signaling
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FOXA1 transcription factor network
|
|
Notch-mediated HES/HEY networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
FOXA2 and FOXA3 transcription factor networks
|
|
Glucocorticoid receptor regulatory network
|
|
AP-1 transcription factor network
|
|
PathWhiz Pathway
|
Kidney Function
|
|
Reactome
|
Nuclear Receptor transcription pathway
|
|
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3R-HSA-1368108:BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
WikiPathways
|
ACE Inhibitor PathwayWP706:SIDS Susceptibility Pathways
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
|
Androgen receptor signaling pathwayWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
SIDS Susceptibility Pathways
|
|
Endoderm Differentiation
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Adipogenesis
|
|
Circadian Clock
|
| References |
| REF 1 | J Med Chem. 1998 Oct 22;41(22):4354-9.5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. |
|---|
